Acceleron Careers

Patients

At Acceleron, we are dedicated to bringing innovative, life-changing therapies to patients with a wide range of serious and rare diseases. Our scientific leadership and broad platform have enabled us to produce a rich pipeline of important new medicines for rare blood disorders, neuromuscular, and pulmonary diseases.

  • Luspatercept-aamt is a first-in-class erythroid (red blood cell) maturation agent being developed to treat patients who have serious blood disorders associated with ineffective erythropoiesis. Discovered by scientists at Acceleron, luspatercept-aamt is a recombinant fusion protein that binds several TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling.
  • ACE-083 is being studied in a two-part Phase 2 trial for the treatment of Charcot-Marie-Tooth (CMT) disease.
  • In our pulmonary program, our newest disease focus area, we have initiated the PULSAR and SPECTRA Phase 2 trials in pulmonary arterial hypertension (PAH).

The clinical trials listed below are Acceleron or partner-sponsored trials, some of which are actively recruiting patients. Each trial in the list contains a link to clinicaltrials.gov, where you will find a full description and contact information.


DrugStudy PhaseDisease
LuspaterceptMEDALIST Phase III*Lower-Risk MDS
LuspaterceptCOMMANDS Phase III*Low or Intermediate Risk MDS
LuspaterceptBEYOND Phase II*Beta-Thalassemia
LuspaterceptPhase II*Myelofibrosis
LuspaterceptPhase II ExtensionMDS
LuspaterceptPhase II ExtensionBeta-Thalassemia
LuspaterceptPhase IIAnemia in Lower-Risk MDS
LuspaterceptPhase IIBeta-Thalassemia
ACE-083Phase IIFacioscapulohumeral Muscular Dystrophy
ACE-083Phase IICharcot-Marie-Tooth Disease
SotaterceptPULSAR Phase IIPulmonary Arterial Hypertension
SotaterceptSPECTRA Phase IIPulmonary Arterial Hypertension
Acceleron trials listed as recruiting or active on www.clinicaltrials.gov

* Celgene-sponsored